Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

  • October 8, 2025

  • 3 min

Share

Clinical Scorecard: Molecular Testing Essential for Accurate Diagnosis of Mucinous Tubular and Spindle Cell Carcinoma versus Papillary Renal Cell Carcinoma

At a Glance

CategoryDetail
ConditionMucinous tubular and spindle cell carcinoma (MTSCC) and papillary renal cell carcinoma (PRCC)
Key MechanismsPresence of papillary formations in both MTSCC and PRCC complicates diagnosis; molecular and chromosomal testing distinguishes between the two
Target PopulationPatients with kidney tumors suspected to be MTSCC or PRCC
Care SettingPathology and oncology diagnostic laboratories, clinical genomics laboratories

Key Highlights

  • Papillary formations, previously considered a hallmark of PRCC, were found in all studied MTSCC cases.
  • Molecular and chromosomal analysis is critical to differentiate MTSCC from PRCC, especially in small biopsy specimens.
  • Accurate diagnosis via molecular testing enables more effective and tailored treatment planning.

Guideline-Based Recommendations

Diagnosis

  • Perform molecular and chromosomal testing to distinguish MTSCC from PRCC when papillary formations are present.
  • Use molecular testing especially in small specimen samples such as fine needle aspiration biopsies.

Management

  • Base treatment plans on accurate molecular diagnosis to optimize patient outcomes.

Monitoring & Follow-up

  • Further research and clinical correlation are needed to understand the clinical behavior of MTSCC tumors with papillary features.

Risks

  • Risk of misdiagnosis if relying solely on morphological features like papillary formation without molecular confirmation.

Patient & Prescribing Data

Patients with kidney tumors exhibiting papillary features on histology

Accurate molecular diagnosis guides selection of appropriate therapeutic strategies tailored to tumor subtype.

Clinical Best Practices

  • Incorporate molecular and chromosomal testing routinely in the diagnostic workup of kidney tumors with ambiguous histologic features.
  • Avoid reliance solely on papillary morphology for diagnosis of PRCC versus MTSCC.
  • Collaborate between pathology and clinical genomics laboratories to ensure precise tumor classification.

Related Resources & Content

Original Source(s)

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

  • October 8, 2025

Related Content

Endogenous Competition of circ_001024 for miR-145-3p: Implications for GLUT5 Regulation in Renal Cell Carcinoma

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

  • 1 min
International Kidney Cancer Collaboration with Leadership from Philadelphia

Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for a steep rise in the number of cases,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, and senior author of a landmark international study published in European Urology, which demonstrates that if current trends continue, kidney cancer cases could double by 2050

  • December 2, 2025

  • 3 min